Elaine Chen from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children - 8 days ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - about 2 months ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - about 2 months ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 2 months ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - 3 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 3 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 4 months ago STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 4 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 4 months ago Listen: Drug pricing drops & psychedelics under fire - 4 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 5 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 5 months ago
2	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children - 8 days ago STAT+: Schizophrenia drug AbbVie picked up in $9 billion acquisition fails in key trials - about 1 month ago AstraZeneca falls on reports of Chinese probe - about 1 month ago STAT+: Novo Nordisk reports continued growth in obesity drug sales - about 1 month ago Investors reevaluate this year’s obesity darling - about 2 months ago STAT+: With new Wegovy data in hand, Novo Nordisk will file for approval in MASH - about 2 months ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - about 2 months ago STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - about 2 months ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - about 2 months ago STAT+: Ozempic linked to lower risk of Alzheimer’s diagnosis in observational study - about 2 months ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 2 months ago More evidence on GLP-1s and opioid addiction - 2 months ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - 3 months ago Can GLP-1 drugs help with type 1 diabetes? - 3 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 3 months ago Moderna cuts spending, and Sarepta’s ‘curse’ on Califf - 3 months ago STAT+: Gilead’s twice-yearly antiviral protects against HIV infection in second large trial - 3 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 4 months ago STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 4 months ago BioMarin’s big day today - 4 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 4 months ago Does Ozempic increase the risk of suicidal thoughts? - 4 months ago STAT+: Lilly’s Zepbound slashed risk of developing diabetes - 4 months ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 4 months ago Listen: Drug pricing drops & psychedelics under fire - 4 months ago Moderna is still in a Covid hangover - 5 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 5 months ago venBio raises $528 million for its fifth fund - 5 months ago Merck lays off workers amid rough pharma job market - 5 months ago Contradictory coverage decisions in North Carolina - 5 months ago STAT+: Gilead’s chief medical officer to leave as R&D efforts stall - 5 months ago It’s happy hour (for now) for Alnylam - 5 months ago As GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will move on without them - 5 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 5 months ago Can you get satiety with GLP-1s without the nausea? - 5 months ago STAT+: Pfizer says it will advance once-daily GLP-1 pill after all - 5 months ago STAT+: Eli Lilly to acquire Morphic for $3.2 billion - 6 months ago STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry - 6 months ago What do Parkinson’s and obesity have in common? - 6 months ago STAT+: Ozempic cut risk of death in diabetes patients with chronic kidney disease - 7 months ago STAT+: In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu - 7 months ago STAT+: 4 burning questions about Amgen’s obesity drug, a potential Wegovy and Zepbound competitor - 8 months ago STAT+: Amgen goes all in on injectable obesity drug as it scraps early-stage pill - 8 months ago Large trial challenges common practice of prescribing beta blockers after heart attack - 9 months ago STAT+: Alnylam’s twice-a-year drug lowered blood pressure when combined with common pills - 9 months ago STAT+: Positive trial results set up obesity drug Wegovy for use against heart failure - 9 months ago Parkinson’s disease may be helped by GLP-1 drug, new study finds - 9 months ago Ozempic-like drugs linked to low, but increased risk of post-endoscopy pneumonia, study finds - 9 months ago STAT+: Merck drug for rare cardiovascular condition approved in U.S. - 9 months ago STAT+: Despite new Wegovy coverage, Medicare patients may face high drug costs and other hurdles - 9 months ago
3	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children - 8 days ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - about 2 months ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - about 2 months ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 2 months ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - 3 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 3 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 4 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 4 months ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 4 months ago Listen: Drug pricing drops & psychedelics under fire - 4 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 5 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 5 months ago
4	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Novo Nordisk reports continued growth in obesity drug sales - about 1 month ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 4 months ago
5	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - about 2 months ago
6	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - about 2 months ago STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry - 6 months ago
7	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Pfizer says it will advance once-daily GLP-1 pill after all - 5 months ago
8	Nicholas Florko STAT News Reports on US health business. Washington, DC healthcarepolicy	STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry - 6 months ago
9	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry - 6 months ago